Sanofi-Aventis: French Pharma Giant
Big pharmaceutical stocks in the U.S. have been ailing, but in Europe, the story is different.
Owning big pharma stocks in recent years has pretty much been a prescription for losing money. Product recalls (Vioxx and Bextra, for example), litigation, patent expirations, generic competition, limp new-drug pipelines and unfavorable publicity have buffeted the sector. Stocks such as Pfizer and Eli Lilly have been mostly falling since early 2004.
But over in Europe, pharmaceutical stocks such as Novartis and Roche have been in ruddy good health. Wendell Perkins, co-manager of JohnsonFamily International Value, recommends Sanofi-Aventis, a French pharma giant formed in a 2004 megamerger. Perkins favors Aventis, the world's third largest drugmaker (after Pfizer and GlaxoSmithKline), for its deep, diverse product portfolio and promising pipeline.
Consider: Aventis boasts billion-dollar blockbuster drugs in categories ranging from anti-coagulants (Lovenox and Plavix) and oncology medicines (Taxotene and Eloxatin) to diabetes (Lantus) and insomnia (Ambien) fighters. The company also sells the leading vaccines for afflictions such as influenza and polio. The sources of Aventis's revenues are well balanced geographically: Europe accounts for 40% of sales, the U.S. for 30%, and the rest of the world the remaining 30%.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Aventis's laboratories have been remarkably fertile. They are currently developing 129 products. Perkins thinks Acomplia, an anti-obesity drug expected to receive approval from the Food and Drug Administration in the second half of this year, will be a new blockbuster.
Sanofi-Aventis is still benefiting from large cost savings wrung out of the merged companies. But unlike many U.S. drug companies, sales growth -- 10% in the first quarter of this year -- has remained robust. Trading at $48 a share, Aventis's American depositary receipts (symbol SNY) sell for 14 times the average of analysts' 2006 earnings estimates.
--Andrew Tanzer
To continue reading this article
please register for free
This is different from signing in to your print subscription
Why am I seeing this? Find out more here
-
What Is a Debt-to-Equity Ratio and How Can Investors Use It?
A debt-to-equity ratio is a way to measure how solid a company's financial position is. Here, we take a closer look at what it is and how investors can use it.
By Coryanne Hicks Published
-
Three Gen X Retirement Mistakes for Millennials, Gen Z to Avoid
Many Gen Xers haven’t prioritized saving for retirement and face a crisis as the first generation to retire without substantial support from pension plans.
By Tiffani Potesta Published
-
Stock Market Today: Stocks Soar on Apple Buyback News, Jobs Data
The main indexes rallied hard to end the week thanks to Apple's $110 billion stock repurchase plan and a big April payrolls miss.
By Karee Venema Published
-
Stock Market Today: Stocks Sizzle Ahead of Apple Earnings, Jobs Report
The Nasdaq outperformed in a strong day for stocks thanks to Qualcomm's post-earnings pop.
By Karee Venema Published
-
Stock Market Today: Stocks Pop Then Drop After Fed Meeting
Stocks went on a roller-coaster ride after Fed Chair Powell said interest rates were likely at a sufficiently restrictive level.
By Karee Venema Published
-
Fed Holds Rates Steady at 23-Year High: What the Experts Are Saying
Federal Reserve The Federal Reserve struck a dovish pose even as it kept interest rates unchanged for a sixth straight meeting.
By Dan Burrows Published
-
Stock Market Today: Stocks Sell Off Ahead of Fed Decision
Stocks sold off sharply Tuesday as anxiety set in ahead of Wednesday's policy statement from the Federal Reserve.
By Karee Venema Published
-
Stock Market Today: Markets Post Broad-Based Gains Thanks to Mega-Cap Tech
Stocks get help from a couple of laggard Magnificent 7 stocks.
By Dan Burrows Published
-
Stock Market Today: Markets Soar Amid Strong Earnings for Big Tech
Equities ended the week on an up note thanks to some of the market's biggest names.
By Dan Burrows Published
-
Stock Market Today: Markets Tumble Amid Slower Economic Growth and Rising Prices
Disappointing readings on GDP and inflation helped tank equities.
By Dan Burrows Published